Nasopharyngeal Carcinoma
NPC · Nasopharyngeal cancer · Nasopharynx cancer | ICD-O-3 C11
Nasopharyngeal carcinoma is an Epstein–Barr virus-associated cancer arising in the upper throat behind the nose. It is rare in most Western countries but endemic in Southeast Asia, southern China and parts of North Africa. Because of its deep location and radiosensitivity, intensity-modulated radiotherapy — not surgery — is the primary curative treatment, with chemotherapy added for locally advanced disease.
The nasopharynx sits behind the nasal cavity and above the oropharynx; a small tumour there can be invisible on routine mouth examination. Endemic NPC is usually the non-keratinising subtype and is closely linked to Epstein–Barr virus (EBV), genetic susceptibility and childhood dietary exposures such as salt-preserved fish. Plasma EBV DNA is used both for risk assessment and for monitoring treatment response and recurrence.
NPC differs from other head and neck cancers in three clinically important ways: it is highly radiosensitive and chemosensitive, it has a high rate of neck-node involvement at diagnosis, and surgery is reserved for residual or recurrent disease rather than for initial treatment. A painless upper-neck lump or unilateral middle-ear effusion in an adult from an endemic region should trigger nasopharyngoscopy.
Where in the world is nasopharyngeal carcinoma common?
120,434 new nasopharyngeal cancer cases worldwide were estimated worldwide in 2022 (ASR 1.3 per 100,000 (men 1.9, women 0.7); 15.9% of lip/oral/pharyngeal cancers in 2022). 73,482 deaths worldwide in 2022; 61,442 (83.6%) in Asia.
NPC was the most common lip/oral/pharyngeal subsite in South-Eastern Asia (50.8% of the regional burden), Northern Africa (41.8%) and Eastern Asia (36.9%).
| Region / country | What the data show |
|---|---|
| South-East Asia | 50.8% of all lip/oral/pharyngeal cancers in the region; ~35,889 cases in 2022. Highest national ASRs: Brunei 6.4, Indonesia 6.1, Malaysia 5.9, Singapore 5.4, Vietnam 4.7, Philippines 3.5. Male ASRs reach 9.6 in Indonesia and 8.9 in Malaysia. |
| East Asia / southern China | China recorded 51,010 cases (about 51% of the world total) with an ASR of 2.4; incidence is far higher in southern provinces such as Guangdong and Guangxi than in the north. |
| Northern Africa & the Middle East | NPC is the leading lip/oral/pharyngeal subsite in Northern Africa (41.8%). Algeria recorded 1,608 cases with an ASR of 3.5 (4.8 in men) and 971 deaths; Morocco, Tunisia, Egypt and Sudan also have intermediate endemic rates. |
| South Asia | Maldives had the highest reported ASR worldwide (7.5) but only 36 cases, illustrating how small populations can produce unstable rates. India had 6,519 cases at ASR 0.5. |
| North America & Europe | Rare: US ASR about 0.4 with 2,008 cases; Europe 4,513 cases. Western cases are more often keratinising and more often tobacco/alcohol associated. |
What are the risk factors?
- Epstein–Barr virus infection and high or persistently detectable plasma EBV DNA
- Family clustering and inherited HLA / genetic susceptibility in endemic populations
- Frequent consumption of salt-preserved fish and cured foods, especially in childhood
- Cigarette smoking and heavy alcohol use (stronger association with the keratinising subtype)
- Occupational exposure to wood dust, formaldehyde and certain solvents
- Male sex — incidence is roughly two to three times higher in men
What are the signs and symptoms?
- A painless lump in the upper neck (the most common presenting sign)
- Unilateral nasal obstruction, discharge or nosebleeds
- One-sided middle-ear effusion, muffled hearing, tinnitus or a blocked-ear sensation in an adult
- Persistent headache, facial numbness or double vision from skull-base involvement
- Sore throat, changes in voice, or difficulty opening the mouth in advanced disease
- Unexplained weight loss; rarely, cranial nerve palsies affecting eye movement
Two-to-three-week rule: any head or neck symptom that persists beyond two to three weeks should be examined by an ENT specialist with an endoscope — pain is usually a late feature, not an early one.
How is it diagnosed and staged?
- Nasal endoscopy / nasopharyngoscopy with biopsy of the primary lesion
- MRI of the nasopharynx and neck with contrast — the key test for skull-base, parapharyngeal and nodal extension
- Plasma EBV DNA quantification before treatment (prognostic and useful for surveillance)
- FDG PET-CT or chest/abdominal imaging for N3 or metastatic staging; baseline audiometry and dental assessment
- Pathology classified by WHO subtype (keratinising vs non-keratinising), with EBV-encoded RNA (EBER) in-situ hybridisation when needed
- FNA rather than open biopsy for a neck mass when NPC is suspected
NPC uses a separate AJCC/UICC TNM staging system reflecting its distinct behaviour: early T1 disease can already have bulky nodal involvement, and skull-base or cranial nerve involvement defines T3/T4. Stage I is treated with radiotherapy alone; stage II with radiotherapy ± concurrent chemotherapy; stage III–IVA with induction chemotherapy plus concurrent chemoradiotherapy in current Chinese and international practice.
What are the treatment options?
- Intensity-modulated radiotherapy (IMRT) as the definitive treatment — typically 33 fractions over 6–7 weeks
- Stage I: IMRT alone; Stage II: IMRT with or without concurrent cisplatin-based chemotherapy
- Locally advanced (Stage III–IVA): induction chemotherapy (gemcitabine + cisplatin or TPF) followed by concurrent chemoradiotherapy
- Anti-EGFR (nimotuzumab) or PD-1 immunotherapy (toripalimab, camrelizumab, pembrolizumab) in selected protocols and in recurrent/metastatic disease, per regional guidelines
- Salvage surgery or re-irradiation for local recurrence; systemic therapy for distant metastasis
- Supportive care: nasal irrigation, mouth-opening and neck exercises, skin and oral care, nutrition and swallowing support
Decisions should be made by a multidisciplinary tumour board, with speech, swallowing and appearance considered alongside cancer control. See how treatment changes with stage →
What is the prognosis?
Because NPC is highly radiosensitive, stage I disease has five-year survival commonly above 90%, and modern IMRT series report good control for locoregionally advanced disease. Prognosis worsens with bulky nodal disease, skull-base invasion, high pre-treatment EBV DNA, detectable EBV DNA after treatment and distant metastasis. Over 90% of recurrences occur within five years, so structured follow-up matters.
Survival figures are population averages from registry data, not predictions for an individual. See the follow-up schedule →
Can it be prevented?
- Reduce childhood consumption of salt-preserved fish and cured meats in endemic communities
- Avoid smoking and heavy alcohol use
- There is currently no licensed EBV vaccine; EBV DNA and antibody screening is a research/ high-risk-region strategy, not routine worldwide
- Early nasopharyngoscopy for persistent unilateral nasal or ear symptoms in endemic regions
- Prompt evaluation of a painless upper-neck lump rather than a trial of antibiotics
Prevention by region: HPV vaccine, areca nut, tobacco and UV →
Treatment in China for international patients
China treats the largest number of NPC patients in the world, so endemic-region centres have deep experience with IMRT planning, induction chemotherapy, EBV DNA monitoring and salvage surgery for recurrence. For international patients, the full diagnostic work-up and a 6–7 week radiotherapy course can usually be scheduled without a long wait.
- Bring the original biopsy slides/blocks, MRI DICOM files, EBV DNA results and any prior chemotherapy or radiotherapy records.
- Ask for the written radiotherapy prescription (total dose, fraction number, target volumes) and the chemotherapy schedule in English.
- Discuss the monitoring plan: EBV DNA at defined intervals, nasopharyngoscopy, MRI, and thyroid/ hearing checks after neck irradiation.
- Plan for a 7–10 week stay if radiotherapy is part of treatment, plus time for dental clearance and a post-treatment response scan.
Cost guidance: The original guidance on this site quoted ¥80,000–¥150,000 (about US$11,000–21,000) for a full NPC treatment course; as a planning range for 2026, ¥90,000–¥180,000 for IMRT with chemotherapy is more realistic, with targeted agents or immunotherapy charged separately per cycle. These figures are illustrative budgeting numbers, not a quotation.
Compare the pathway, records checklist and aftercare planning on the international patients page.
All 15 questions about nasopharyngeal carcinoma
Each question has its own page with a direct answer, practical detail and the sources behind it — the same structure used on Dr. Liu’s Chinese knowledge base.
Understanding the disease
3 questionsWhat the tumour is, where in the world it is common, who gets it and why.
Symptoms & diagnosis
3 questionsThe warning signs, the biopsy, the scans and what staging actually means.
Treatment
2 questionsSurgery, radiotherapy, chemotherapy, immunotherapy and organ-preserving options.
Side effects & recovery
1 questionWhat treatment feels like, how side effects are managed, and rehabilitation.
Prognosis & follow-up
2 questionsSurvival figures in context, recurrence risk and the follow-up schedule.
Prevention & risk
2 questionsHPV vaccination, tobacco and areca nut, UV protection and occupational exposure.
Treatment in China
2 questionsWhat international patients should prepare, timelines, costs and aftercare.
Frequently asked questions
What is nasopharyngeal carcinoma?
Nasopharyngeal carcinoma is an Epstein–Barr virus-associated cancer arising in the upper throat behind the nose. It is rare in most Western countries but endemic in Southeast Asia, southern China and parts of North Africa. Because of its deep location and radiosensitivity, intensity-modulated radiotherapy — not surgery — is the primary curative treatment, with chemotherapy added for locally advanced disease.
Where in the world is nasopharyngeal carcinoma most common?
Nasopharyngeal Carcinoma is not evenly distributed: the highest-burden regions are South-East Asia, East Asia / southern China and Northern Africa & the Middle East. In 2022 there were 120,434 new nasopharyngeal cancer cases worldwide worldwide (ASR 1.3 per 100,000 (men 1.9, women 0.7); 15.9% of lip/oral/pharyngeal cancers in 2022), with marked country-to-country variation driven by local exposures such as tobacco, areca nut, oncogenic viruses, ultraviolet radiation and occupational carcinogens.
What are the risk factors for nasopharyngeal carcinoma?
The main recognised risk factors for nasopharyngeal carcinoma are epstein–Barr virus infection and high or persistently detectable plasma EBV DNA, family clustering and inherited HLA / genetic susceptibility in endemic populations and frequent consumption of salt-preserved fish and cured foods, especially in childhood. Risks differ by region: South-East Asia has a distinctive exposure pattern, so a patient's country of residence is part of the risk assessment. Having a risk factor does not mean a person will develop cancer.
What are the early signs of nasopharyngeal carcinoma?
The common early signs are a painless lump in the upper neck (the most common presenting sign), unilateral nasal obstruction, discharge or nosebleeds, one-sided middle-ear effusion, muffled hearing, tinnitus or a blocked-ear sensation in an adult and persistent headache, facial numbness or double vision from skull-base involvement. Head and neck tumours often cause mild, one-sided symptoms that mimic a cold, a dental problem or a sore throat. Any symptom in the head or neck that persists for more than two to three weeks needs an ENT examination rather than repeated antibiotics.
How is nasopharyngeal carcinoma diagnosed and staged?
Diagnosis requires a tissue biopsy read by a head and neck pathologist, supported by endoscopic examination and contrast CT or MRI of the neck; PET-CT is added when nodal or distant spread is suspected. Staging uses the AJCC TNM system and guides whether surgery, radiotherapy, chemoradiotherapy or systemic therapy is the primary treatment.
What are the treatment options for nasopharyngeal carcinoma?
Treatment is stage- and site-specific, and usually combines intensity-modulated radiotherapy (IMRT) as the definitive treatment — typically 33 fractions over 6–7 weeks, stage I: IMRT alone; Stage II: IMRT with or without concurrent cisplatin-based chemotherapy and locally advanced (Stage III–IVA): induction chemotherapy (gemcitabine + cisplatin or TPF) followed by concurrent chemoradiotherapy. Early-stage disease is generally treated with one modality (surgery or radiotherapy), while locally advanced disease needs combined modality treatment planned by a multidisciplinary team.
What is the prognosis for nasopharyngeal carcinoma?
Because NPC is highly radiosensitive, stage I disease has five-year survival commonly above 90%, and modern IMRT series report good control for locoregionally advanced disease. Prognosis worsens with bulky nodal disease, skull-base invasion, high pre-treatment EBV DNA, detectable EBV DNA after treatment and distant metastasis. Over 90% of recurrences occur within five years, so structured follow-up matters.
Can nasopharyngeal carcinoma be prevented?
Many cases are preventable. The most useful steps for nasopharyngeal carcinoma are reduce childhood consumption of salt-preserved fish and cured meats in endemic communities, avoid smoking and heavy alcohol use and there is currently no licensed EBV vaccine; EBV DNA and antibody screening is a research/ high-risk-region strategy, not routine worldwide. Prevention works best before exposure begins, but stopping tobacco, areca nut and heavy alcohol use still lowers risk after many years of use.
Why is nasopharyngeal carcinoma treated with radiotherapy rather than surgery?
The nasopharynx lies deep behind the nose, close to the skull base, major blood vessels and cranial nerves, so wide surgical removal is rarely feasible at diagnosis. Non-keratinising NPC is also exceptionally radiosensitive and chemosensitive, making IMRT with or without chemotherapy the curative standard. Surgery is reserved for residual or locally recurrent disease.
What does the EBV DNA blood test tell me?
Plasma EBV DNA reflects tumour-derived viral DNA in the bloodstream. A high pre-treatment level is associated with more advanced disease and higher recurrence risk; a level that becomes undetectable after treatment suggests a good response, while a rising level on follow-up can signal recurrence before it is visible on imaging.
What side effects should I expect during IMRT for nasopharyngeal cancer?
Common acute effects are skin redness and peeling on the neck, dry mouth and thickened saliva, taste loss, mouth sores, fatigue, nasal congestion and temporary hearing changes from middle-ear fluid. Most improve over weeks to months; dry mouth and reduced taste can persist six to twelve months or longer.
How is recurrence detected after nasopharyngeal cancer treatment?
Follow-up combines symptom review, nasopharyngoscopy, neck examination, serial plasma EBV DNA and periodic MRI of the nasopharynx and neck; PET-CT is used when recurrence or distant metastasis is suspected. More than 90% of recurrences appear within five years, so visits are most frequent in the first two to three years.
Is nasopharyngeal carcinoma hereditary or contagious?
NPC is not contagious in the ordinary sense, although EBV infection is extremely common worldwide and is transmitted through saliva. It is not a classic inherited cancer, but familial clustering and specific HLA and genetic variants contribute to the striking ethnic and geographic pattern, alongside childhood diet and environmental exposures.
What does a full nasopharyngeal cancer treatment course in China involve?
It typically involves one to two weeks of staging and pre-treatment preparation (MRI, PET-CT if indicated, EBV DNA, dental clearance, audiometry, nutrition), two to three cycles of induction chemotherapy when indicated, then six to seven weeks of daily IMRT with concurrent chemotherapy, followed by a response assessment and a written follow-up plan.
How much does nasopharyngeal carcinoma treatment cost in China?
As an illustrative planning range, IMRT with concurrent chemotherapy is commonly budgeted at ¥90,000–¥180,000 (roughly US$12,500–25,000). Induction chemotherapy, nimotuzumab, PD-1 immunotherapy, PET-CT and management of complications are additional. These are budgeting figures, not a quotation.
Sources for this topic
- Nasopharyngeal cancer statistics (GLOBOCAN 2022 country rankings)
- Nasopharyngeal Carcinoma in Southeast Asia: Current Landscape and Future Priorities
- Global Cancer Observatory (GLOBOCAN 2022)
- Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022
- NCCN Guidelines for Patients: Head and Neck Cancers
- Head and Neck Cancers (patient information)
- IARC Monographs on the Identification of Carcinogenic Hazards to Humans (tobacco, areca nut, UV radiation, EBV, HPV)
Ask about nasopharyngeal carcinoma treatment in China
Send your pathology report, biomarker results and imaging for a written preliminary opinion before making travel plans.
What to send Contact the clinicMedical disclaimer: This knowledge base is general information for people researching head and neck tumours, not a diagnosis or treatment plan. It does not replace an examination by a qualified physician. Survival figures are population averages, not predictions for an individual. Treatment and cost estimates for China are illustrative only and must be confirmed in writing after your records have been reviewed. If you have a symptom lasting more than two to three weeks, see a doctor promptly.